aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT(TM) Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)

Stock Information for aTyr Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About aTyr Pharma Inc.

 aTyr Pharma to Present at Upcoming Investor Conferences
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025
aTyr Pharma to Participate in April Investor Conferences
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.